These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31140832)

  • 1. An update of urine and blood metabolomics in chronic kidney disease.
    Kalantari S; Nafar M
    Biomark Med; 2019 May; 13(7):577-597. PubMed ID: 31140832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of renal metabolomics.
    Kalim S; Rhee EP
    Kidney Int; 2017 Jan; 91(1):61-69. PubMed ID: 27692817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease.
    Chen DQ; Cao G; Chen H; Liu D; Su W; Yu XY; Vaziri ND; Liu XH; Bai X; Zhang L; Zhao YY
    Redox Biol; 2017 Aug; 12():505-521. PubMed ID: 28343144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomics and metabolomics in nephrology.
    Atzler D; Schwedhelm E; Zeller T
    Nephrol Dial Transplant; 2014 Aug; 29(8):1467-74. PubMed ID: 24366899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue, urine and blood metabolite signatures of chronic kidney disease in the 5/6 nephrectomy rat model.
    Hanifa MA; Skott M; Maltesen RG; Rasmussen BS; Nielsen S; Frøkiær J; Ring T; Wimmer R
    Metabolomics; 2019 Aug; 15(8):112. PubMed ID: 31422467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomics in chronic kidney disease.
    Zhao YY
    Clin Chim Acta; 2013 Jun; 422():59-69. PubMed ID: 23570820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma biomarker discovery for early chronic kidney disease diagnosis based on chemometric approaches using LC-QTOF targeted metabolomics data.
    Benito S; Sánchez-Ortega A; Unceta N; Jansen JJ; Postma G; Andrade F; Aldámiz-Echevarria L; Buydens LMC; Goicolea MA; Barrio RJ
    J Pharm Biomed Anal; 2018 Feb; 149():46-56. PubMed ID: 29100030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics in chronic kidney disease: Strategies for extended metabolome coverage.
    Gagnebin Y; Julien B; Belén P; Serge R
    J Pharm Biomed Anal; 2018 Nov; 161():313-325. PubMed ID: 30195171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rule-Mining for the Early Prediction of Chronic Kidney Disease Based on Metabolomics and Multi-Source Data.
    Luck M; Bertho G; Bateson M; Karras A; Yartseva A; Thervet E; Damon C; Pallet N
    PLoS One; 2016; 11(11):e0166905. PubMed ID: 27861591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-QTOF-MS-based targeted metabolomics of arginine-creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease.
    Benito S; Sánchez A; Unceta N; Andrade F; Aldámiz-Echevarria L; Goicolea MA; Barrio RJ
    Anal Bioanal Chem; 2016 Jan; 408(3):747-60. PubMed ID: 26537926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary proteome and metabolome in dogs (Canis lupus familiaris): The effect of chronic kidney disease.
    Ferlizza E; Isani G; Dondi F; Andreani G; Vasylyeva K; Bellei E; Almeida AM; Matzapetakis M
    J Proteomics; 2020 Jun; 222():103795. PubMed ID: 32335294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabonomic biomarkers for risk factors of chronic kidney disease.
    Ye L; Mao W
    Int Urol Nephrol; 2016 Apr; 48(4):547-52. PubMed ID: 26897037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.
    Rysz J; Gluba-Brzózka A; Franczyk B; Jabłonowski Z; Ciałkowska-Rysz A
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a better understanding of chronic kidney disease with complementary chromatographic methods hyphenated with mass spectrometry for improved polar metabolome coverage.
    Gagnebin Y; Pezzatti J; Lescuyer P; Boccard J; Ponte B; Rudaz S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():9-18. PubMed ID: 30951967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.
    Kalim S; Wald R; Yan AT; Goldstein MB; Kiaii M; Xu D; Berg AH; Clish C; Thadhani R; Rhee EP; Perl J
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):436-444. PubMed ID: 29444900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease.
    Cañadas-Garre M; Anderson K; McGoldrick J; Maxwell AP; McKnight AJ
    J Proteomics; 2019 Feb; 193():93-122. PubMed ID: 30292816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-source data integration approach reveals novel associations between metabolites and renal outcomes in the German Chronic Kidney Disease study.
    Altenbuchinger M; Zacharias HU; Solbrig S; Schäfer A; Büyüközkan M; Schultheiß UT; Kotsis F; Köttgen A; Spang R; Oefner PJ; Krumsiek J; Gronwald W
    Sci Rep; 2019 Sep; 9(1):13954. PubMed ID: 31562371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics and renal disease.
    Rhee EP
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):371-9. PubMed ID: 26050125
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.